Shares of Revolution Medicines, Inc. (RVMD) are gaining over 7% on Wednesday morning after the company reported progress in RAS cancer therapy.
RVMD is currently trading at $35.48, up $2.49 or 7.55%, on the Nasdaq. The stock opened its trading at $33.98 after closing Wednesday at $32.99. The stock has traded between $15.44 and $37.50 in the past 52-week period.
Revolution Medicines, a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, announced the publication of a peer-reviewed research paper in Cancer Discovery.
The scientific paper details the discovery and preclinical to clinical translation for RMC-6236, an investigational RAS(ON) multi-selective inhibitor, and includes exemplary case studies from the current Phase 1/1b clinical trial demonstrating the initial anti-tumor activity of RMC-6236.
For comments and feedback: editorial@rttnews.com